In the video interview above, and article which follows, Algernon Pharmaceuticals CEO Christopher J. Moreau shares that the Company (AGN) has announced plans for a 180-patient, 90-day Phase 2b clinical study of NP-120 for chronic cough in Q3 of 2023.

Ifenprodil represents a novel first-in-class potential treatment for chronic cough and is thought to interfere with central signalling in the brain, suppressing the urge to cough.

The decision to advance the study is based on positive data previously reported on July 28, 2022, from the company’s Phase 2a study of Idiopathic Pulmonary Fibrosis (IPF) and chronic cough, where Ifenprodil showed a significant improvement in mean objective 24-hour and waking cough counts in patients after 4 and 12 weeks.

Algernon previously announced on January 14, 2022, that it had received positive feedback from the U.S. Food and Drug Administration (U.S. FDA) at its pre-Investigational New Drug (pre-IND) meeting for its investigation of Ifenprodil solely for the treatment of chronic cough. The company has since engaged in further discussions with the U.S. FDA and plans to file an investigational new drug (IND) application shortly.

Read full article here